Publicaciones en las que colabora con Alfonso Jesús Domínguez-Gil Hurlé (24)

2011

  1. Modification of the EMIT immunoassay for the measurement of unbound mycophenolic acid in plasma

    Clinical Biochemistry, Vol. 44, Núm. 2-3, pp. 260-263

2010

  1. Clinical repercussions of analytical interferences due to aldosterone antagonists in digoxin immunoassays: An assessment

    Therapeutic Drug Monitoring, Vol. 32, Núm. 2, pp. 169-176

2009

  1. Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients

    Journal of Pharmacy and Pharmacology, Vol. 61, Núm. 6, pp. 759-766

2007

  1. Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients

    Intensive Care Medicine, Vol. 33, Núm. 2, pp. 279-285

2004

  1. Pharmacokinetic basis for the use of extended interval dosage regimens of gentamicin in neonates

    Journal of Antimicrobial Chemotherapy, Vol. 54, Núm. 1, pp. 193-198

1999

  1. Population pharmacokinetics of amikacin in patients with haematological malignancies

    Journal of Antimicrobial Chemotherapy, Vol. 44, Núm. 2, pp. 235-242

1998

  1. Multicriteria decision analysis for determining drug therapy for intermittent claudication

    Methods and Findings in Experimental and Clinical Pharmacology, Vol. 20, Núm. 5, pp. 425-431

1997

  1. Minimizing digoxin-like immunoreactivity with TDx digoxin in dialysis patients [1]

    Therapeutic Drug Monitoring

1996

  1. Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies

    Clinical Pharmacology and Therapeutics, Vol. 60, Núm. 3, pp. 332-340

  2. Influence of pharmacokinetic model on vancomycin peak concentration targets

    Therapeutic Drug Monitoring, Vol. 18, Núm. 2, pp. 145-148

  3. Pharmacokinetics of amikacin in intensive care unit patients

    Journal of Clinical Pharmacy and Therapeutics, Vol. 21, Núm. 6, pp. 417-421

1994

  1. ANALISIS DE DECISION PARA EVALUAR LA RELACION COSTE-EFECTIVIDAD DE LOS MEDIOS DE CONTRASTE DE BAJA OSMOLARIDAD EN UROGRAFIAS INTRAVENOSAS

    Farmacia Clinica, Vol. 11, Núm. 1, pp. 9-20

1992

  1. Decision analysis to assess cost-effectiveness of low-osmolality contrast medium for intravenous urography

    American Journal of Hospital Pharmacy, Vol. 49, Núm. 3, pp. 577-584

  2. EL METAANALISIS COMO TECNICA CUANTITATIVA DE LAS REVISIONES DE LA LITERATURA

    Farmacia Hospitalaria, Vol. 16, Núm. 4, pp. 225-234

1991

  1. H2-receptor antagonists and acute intermittent porphyria [3]

    American Journal of Hospital Pharmacy

1990

  1. ANALISIS DE DECISION EN LA TERAPEUTICA ANTIBIOTICA

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 8, Núm. 4, pp. 199-207

  2. Decision analysis applied to selection of histamine H2-receptor antagonists for the formulary

    American Journal of Hospital Pharmacy, Vol. 47, Núm. 9, pp. 2002-2006

1988

  1. Farmacia hospilataria XXXII

    Sociedad Española de Farmacia Hospitalaria

1987

  1. Bioavailability of rectally administered naproxen

    International Journal of Pharmaceutics, Vol. 38, Núm. 1-3, pp. 117-122

1985

  1. Pharmacokinetics and initial distribution of a new neuroleptic agent picobenzide (M-14012-4)

    International Journal of Clinical Pharmacology Therapy and Toxicology, Vol. 23, Núm. 5, pp. 233-237